|
Name |
Trichodermol
|
Molecular Formula | C15H22O3 | |
IUPAC Name* |
(1S,2R,7R,9R,11R,12S)-1,2,5-trimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-11-ol
|
|
SMILES |
CC1=C[C@@H]2[C@](CC1)([C@]3([C@@H](C[C@H]([C@@]34CO4)O2)O)C)C
|
|
InChI |
InChI=1S/C15H22O3/c1-9-4-5-13(2)11(6-9)18-12-7-10(16)14(13,3)15(12)8-17-15/h6,10-12,16H,4-5,7-8H2,1-3H3/t10-,11-,12-,13+,14-,15+/m1/s1
|
|
InChIKey |
XSUVNTHNQMGPIL-LACSLYJWSA-N
|
|
Synonyms |
Trichodermol; Roridin C; 2198-93-8; 709J50QEIQ; (2S,2'R,4'R,5'S,5a'R,9a'R)-5',5a',8'-trimethyl-2',3',4',5',5a',6',7',9a'-octahydrospiro[oxirane-2,10'-[2,5]methanobenzo[b]oxepin]-4'-ol; TRICHODERMOL [MI]; UNII-709J50QEIQ; CHEMBL2047177; BRN 1287601; 12,13-Epoxytrichothec-9-en-4-beta-ol; Trichothec-9-en-4-beta-ol, 12,13-epoxy-; (4-beta)-12,13-Epoxytrichothec-9-en-4-ol; 4.BETA.-HYDROXY-12,13-EPOXYTRICHOTHEC-9-ENE; Q26840798; Trichothec-9-en-4-ol, 12,13-epoxy-, (4-beta)-; TRICHOTHEC-9-EN-4-OL, 12,13-EPOXY-, (4.BETA.)-; (1S,2R,7R,9R,11R,12S)-1,2,5-trimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-11-ol
|
|
CAS | 2198-93-8 | |
PubChem CID | 12315016 | |
ChEMBL ID | CHEMBL2047177 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 250.33 | ALogp: | 1.2 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 42.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 18 | QED Weighted: | 0.531 |
Caco-2 Permeability: | -4.815 | MDCK Permeability: | 0.00001490 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.374 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.011 |
Blood-Brain-Barrier Penetration (BBB): | 0.237 | Plasma Protein Binding (PPB): | 64.36% |
Volume Distribution (VD): | 1.753 | Fu: | 27.48% |
CYP1A2-inhibitor: | 0.059 | CYP1A2-substrate: | 0.551 |
CYP2C19-inhibitor: | 0.162 | CYP2C19-substrate: | 0.839 |
CYP2C9-inhibitor: | 0.062 | CYP2C9-substrate: | 0.072 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.154 |
CYP3A4-inhibitor: | 0.156 | CYP3A4-substrate: | 0.376 |
Clearance (CL): | 6.101 | Half-life (T1/2): | 0.429 |
hERG Blockers: | 0.044 | Human Hepatotoxicity (H-HT): | 0.775 |
Drug-inuced Liver Injury (DILI): | 0.164 | AMES Toxicity: | 0.866 |
Rat Oral Acute Toxicity: | 0.292 | Maximum Recommended Daily Dose: | 0.453 |
Skin Sensitization: | 0.457 | Carcinogencity: | 0.125 |
Eye Corrosion: | 0.024 | Eye Irritation: | 0.523 |
Respiratory Toxicity: | 0.906 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003277 | 0.683 | D06IIB | 0.255 | ||||
ENC001879 | 0.607 | D0L2LS | 0.253 | ||||
ENC005756 | 0.557 | D04GJN | 0.245 | ||||
ENC006152 | 0.440 | D0Y2YP | 0.243 | ||||
ENC001856 | 0.424 | D0Y7IU | 0.239 | ||||
ENC004000 | 0.423 | D04QNO | 0.239 | ||||
ENC004001 | 0.380 | D0Z1XD | 0.236 | ||||
ENC004774 | 0.367 | D0U3GL | 0.236 | ||||
ENC002696 | 0.351 | D02JNM | 0.236 | ||||
ENC003173 | 0.351 | D0P0HT | 0.235 |